Elicio Therapeutics Q2 net loss widens

Elicio Therapeutics

07/08/2025 21:56

Overview

Elicio Q2 net loss widens to $10.6 mln from $7.2 mln in 2024

R&D expenses decrease due to reduced clinical trial manufacturing costs

Co secures $10 mln in additional financing, extending cash runway into Q1 2026

IDMC recommends continuation of ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis

Outlook

Company expects event-driven final analysis focused on disease-free survival in Q4 2025

Current cash supports operations into Q1 2026

Result Drivers

R&D EXPENSES - Decrease in R&D expenses due to reduced clinical trial manufacturing costs

FINANCING - Secured $10 mln financing to extend cash runway into Q1 2026

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
-$10.56 mln
Q2 Basic EPS
-$0.66
Q2 Income from Operations
-$10.09 mln
Q2 Operating Expenses
$10.09 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Elicio Therapeutics Inc is $12.50, about 25% above its August 6 closing price of $9.37

Press Release: ID:nGNX8pGrz7

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)